Logo

MNG Laboratories Xpress Actionable Epilepsy Panel

Apr 05, 2018

MNG Laboratories has announced the commercial launch of its MNG Xpress Actionable Epilepsy panel, a DNA-sequencing assay that uses a standard capture hybridization method to sequence the coding regions of exons. The panel contains a targeted list of 69 epilepsy and seizure-related genes that the company claims are immediately actionable via seizures, pharmacological interventions, and dietary changes. In addition, the panel has a guaranteed turnaround time of less than two weeks for results.   

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.